Close Menu

NEW YORK – SomaLogic said today that is has entered a new agreement with drugmaker Novartis to use its SomaScan proteomics platform in drug discovery and development efforts.

Under the agreement, which is slated to last 10 years, SomaLogic will analyze at least 250,000 clinical samples provided by Novartis and use the data from these analyses to drive its own proteomic test development work.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.